Skip to content

Enterprise value at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$2.02B-67.2%
Biogen logo
BiogenBIIB
$30.08B+34.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.41B+18.5%
Insmed logo
InsmedINSM
$35.25B+142%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$2.41B+228%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$1.08B+368%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s enterprise value?
Solid Biosciences Inc. (SLDB) reported enterprise value of $431.98M in Q1 2026.
How has Solid Biosciences Inc.'s enterprise value changed year-over-year?
Solid Biosciences Inc.'s enterprise value increased by 333.2% year-over-year, from $99.72M to $431.98M.
What is the long-term trend for Solid Biosciences Inc.'s enterprise value?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s enterprise value has grown at a -10.2% compound annual growth rate (CAGR), from $686.66M to $400.67M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.